Matchpoint Therapeutics
Cambridge, US · Founded 2021 · 3 known investors
Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
Founders & leadership
AT
Andre TurenneinExecutive
Board
JH
Jason HaflerBoard director
BB
Bruce BoothBoard director
DB
Daniel BeckerBoard director
Investors · 3
Reported raises · per SEC filings
Form D private placements$42M disclosed across 1 round · 2022
▶$42MraisedOct 2022 · 15 investors · PharmaceuticalsRule 506(b)
▶$42MraisedOct 2022 · 15 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Jason HaflerDirector
- Andre TurenneExecutive Officer, Director
- Bruce BoothDirector
- Daniel BeckerDirector
- Offering amount
- $70M
- Amount sold
- $42M
- First sale
- Oct 2022
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Matchpoint Therapeutics do?
- Discovering precision small molecule medicines that harness the power of covalency to transform the treatment of immune diseases.
- Who are Matchpoint Therapeutics's investors?
- Matchpoint Therapeutics's investors include Access Biotechnology, Digitalis Ventures, Sanofi Ventures.
- How much funding has Matchpoint Therapeutics raised?
- Matchpoint Therapeutics has disclosed $42M raised across 1 round.
- Where is Matchpoint Therapeutics headquartered?
- Matchpoint Therapeutics is headquartered in Cambridge, US.